Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
rVSV-ΔG-SARS-CoV-2-S is a clinical stage (Phase 2) replication competent recombinant vaccine against SARS-CoV-2. To evaluate the safety profile of the vaccine, a series of non-clinical safety, immunogenicity and efficacy studies were conducted in four animal species, using multiple doses (up to 108 Plaque Forming Units/animal) and dosing regimens. There were no treatment-related mortalities or any noticeable clinical signs in any of the studies. Compared to unvaccinated controls, hematology and biochemistry parameters were unremarkable and no adverse histopathological findings. There was no detectable viral shedding in urine, nor viral RNA detected in whole blood or serum samples seven days post vaccination. The rVSV-ΔG-SARS-CoV-2-S vaccination gave rise to neutralizing antibodies, cellular immune responses, and increased lymphocytic cellularity in the spleen germinal centers and regional lymph nodes. No evidence for neurovirulence was found in C57BL/6 immune competent mice or in highly sensitive type I interferon knock-out mice. Vaccine virus replication and distribution in K18-human Angiotensin-converting enzyme 2-transgenic mice showed a gradual clearance from the vaccination site with no vaccine virus recovered from the lungs. The nonclinical data suggest that the rVSV-ΔG-SARS-CoV-2-S vaccine is safe and immunogenic. These results supported the initiation of clinical trials, currently in Phase 2.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Archives of toxicology - 96(2022), 3 vom: 03. März, Seite 859-875 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Madar-Balakirski, Noa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.02.2022 Date Revised 06.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00204-021-03214-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335669867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335669867 | ||
| 003 | DE-627 | ||
| 005 | 20231225230357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00204-021-03214-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335669867 | ||
| 035 | |a (NLM)35032184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Madar-Balakirski, Noa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.02.2022 | ||
| 500 | |a Date Revised 06.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a rVSV-ΔG-SARS-CoV-2-S is a clinical stage (Phase 2) replication competent recombinant vaccine against SARS-CoV-2. To evaluate the safety profile of the vaccine, a series of non-clinical safety, immunogenicity and efficacy studies were conducted in four animal species, using multiple doses (up to 108 Plaque Forming Units/animal) and dosing regimens. There were no treatment-related mortalities or any noticeable clinical signs in any of the studies. Compared to unvaccinated controls, hematology and biochemistry parameters were unremarkable and no adverse histopathological findings. There was no detectable viral shedding in urine, nor viral RNA detected in whole blood or serum samples seven days post vaccination. The rVSV-ΔG-SARS-CoV-2-S vaccination gave rise to neutralizing antibodies, cellular immune responses, and increased lymphocytic cellularity in the spleen germinal centers and regional lymph nodes. No evidence for neurovirulence was found in C57BL/6 immune competent mice or in highly sensitive type I interferon knock-out mice. Vaccine virus replication and distribution in K18-human Angiotensin-converting enzyme 2-transgenic mice showed a gradual clearance from the vaccination site with no vaccine virus recovered from the lungs. The nonclinical data suggest that the rVSV-ΔG-SARS-CoV-2-S vaccine is safe and immunogenic. These results supported the initiation of clinical trials, currently in Phase 2 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a Nonclinical | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a G protein, vesicular stomatitis virus |2 NLM | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 700 | 1 | |a Rosner, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Melamed, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Politi, Boaz |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Tamir, Hadas |e verfasserin |4 aut | |
| 700 | 1 | |a Yahalom-Ronen, Yfat |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-David, Elad |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Shmuel, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Sittner, Assa |e verfasserin |4 aut | |
| 700 | 1 | |a Glinert, Itai |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Shay |e verfasserin |4 aut | |
| 700 | 1 | |a Bar-Haim, Erez |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Hila |e verfasserin |4 aut | |
| 700 | 1 | |a Elia, Uri |e verfasserin |4 aut | |
| 700 | 1 | |a Achdout, Hagit |e verfasserin |4 aut | |
| 700 | 1 | |a Erez, Noam |e verfasserin |4 aut | |
| 700 | 1 | |a Rotem, Shahar |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Shlomi |e verfasserin |4 aut | |
| 700 | 1 | |a Nyska, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Yitzhaki, Shmuel |e verfasserin |4 aut | |
| 700 | 1 | |a Beth-Din, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Haim |e verfasserin |4 aut | |
| 700 | 1 | |a Paran, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Israely, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Hadar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of toxicology |d 1974 |g 96(2022), 3 vom: 03. März, Seite 859-875 |w (DE-627)NLM000013374 |x 1432-0738 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2022 |g number:3 |g day:03 |g month:03 |g pages:859-875 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00204-021-03214-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2022 |e 3 |b 03 |c 03 |h 859-875 | ||